Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.56 |
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7103939 | 0.89 | GRIA1 (0.56) | GRIA1GRIA2GRIA3GRIA4 | |
| Hydrochloric Acid SCHEMBL8807636 | 0.88 | GRIA1 (0.55) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL6786694 | 0.81 | GRIA1 (0.53) | GRIA1GRIA2GRIA3GRIA4 | |
| Hydrochloric Acid SCHEMBL6785550 | 0.80 | GRIA1 (0.52) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL6784985 | 0.78 | GRIA1 (0.47) | GRIA1GRIA2GRIA3GRIA4 | |
| Hydrochloric Acid SCHEMBL8809839 | 0.77 | GRIA1 (0.46) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL7984349 | 0.77 | CLPP (0.48) | — | |
| SCHEMBL6785446 | 0.76 | GRIA1 (0.74) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL6789407 | 0.76 | GRIA1 (0.67) | GRIA1GRIA2GRIA3GRIA4 | |
| Hydrochloric Acid SCHEMBL8807575 | 0.75 | GRIA1 (0.66) | GRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703391-B2 | THROMBOSIS, BRAIN DISORDERS, CARDIOVASCULAR DISORDERS, ALZHEIMER'S DISEASE, HUNTINGTON DISEASES | NEUROSEARCH A/S (DK) | 2004-03-09 | — | — | US | claimed |
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-06-19 | — | — | US | claimed |
| EP-0664807-B1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER LAMBERT CO (US) | 1997-09-10 | — | — | EP | claimed |
| EP-0664807-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS. | WARNER LAMBERT CO (US) | 1995-08-02 | — | — | EP | claimed |
| WO-1994009000-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | claimed |
| US-6703391-B2 | THROMBOSIS, BRAIN DISORDERS, CARDIOVASCULAR DISORDERS, ALZHEIMER'S DISEASE, HUNTINGTON DISEASES | NEUROSEARCH A/S (DK) | 2004-03-09 | — | — | US | disclosed |
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-06-19 | — | — | US | disclosed |
| EP-0664807-B1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER LAMBERT CO (US) | 1997-09-10 | — | — | EP | disclosed |
| EP-0664807-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS. | WARNER LAMBERT CO (US) | 1995-08-02 | — | — | EP | disclosed |
| WO-1994009000-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114422-A1 | NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE | CHRNA3, CHRNA7, CHRNB3 | GRIA1 41/4885GRIA2 25/4885GRIA3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.